Business
Jazz Pharmaceuticals Expands Support of the American Heart Association to Raise Awareness of the Link Between Sleep Disorders and Heart Health
Support to include dedicated educational website, science advisory panel, patient video series and strategic alliance across sleep patient advocacy
About this update from Jazz Pharmaceuticals Plc
[{"type":"text","content":"Support to include dedicated educational website, science advisory panel, patient video series and strategic alliance across sleep patient advocacy organizations\nResearch shows that sleep disorders are associated with increased risks of cardiovascular comorbidities, including those with narcolepsy being two- to three-times more likely to have a stroke or heart attack than people without narcolepsy\nDUBLIN, March 30, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced an expansion of its support of the American Heart Association (Association) to provide the sleep disorder community an in-depth understanding of the cardiovascular risks associated with these debilitating disorders. Through this initiative, the Association aims to help people living with sleep disorders determine when professional help may be appropriate and healthcare professionals recognize ways to improve heart health for the patients they treat.\nAn estimated 50 million to 70 million American adults have a chronic, or ongoing, sleep disorder.1 Studies have shown that poor sleep quality and duration can be associated with high blood pressure, elevated cholesterol, stroke and heart attacks.2\n\"With more than two decades of scientific research in complex and difficult-to-treat neurological conditions, we have long been at the forefront of providing therapies and support for patients living with rare and debilitating sleep disorders,\" said Kelvin Tan, MB BCh, MRCPCH, senior vice president and chief medical officer of Jazz Pharmaceuticals. \"Based on our deep expertise in sleep disorders, we are keenly aware of their devastating impact on those diagnosed with these conditions. This is why we are committed to pioneering innovative treatment options for sleep disorders with the possibility to transform the lives of patients and their families.\"\nBecause sleep quality and duration are now considered an essential component for heart and brain health, the American Heart Association recently added sleep to its checklist for measuring cardiovascular health, evolving Life's Simple 7™ cardiovascular health score into Life's Essential 8™.\n\"Research continues to demonstrate that people with sleep disorders like narcolepsy may face even greater risk for heart disease and stroke than the general population,\" said Mitch Elkind, M.D., M.S., FAHA, FAA...